Back to news

CVS Health Gains as Investors React to Raised Outlook and Breakup Plan

Investivoq PriceTracker

CVS Health (CVS) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a combination of stronger quarterly results, higher full-year guidance, and a plan to separate the company into two publicly traded businesses. That mix likely boosted expectations for both near-term earnings power and a potential valuation unlock.

Details:

  • CVS Health posted third-quarter 2026 revenue of $108.4 billion, up 5.4% from a year earlier, with adjusted earnings per share of $2.09.
  • The company raised its full-year 2026 adjusted earnings outlook to at least $8.20 per share and lifted cash flow from operations guidance to at least $15.5 billion.
  • Management said the stronger outlook reflected improvements in the Health Care Benefits and Pharmacy and Consumer Wellness segments.
  • CVS also announced plans to separate into two independent public companies, splitting its healthcare solutions operations from its retail pharmacy and community healthcare business, with completion targeted for the first half of 2028.

    • Sources:

    CVS Health, SEC, Yahoo Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $CVS Insider Trading Activity

    CVS Insider Trades

    $CVS insiders have traded $CVS stock on the open market 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.

    Here’s a breakdown of recent trading of $CVS stock by insiders over the last 6 months:

    • LARRY ROBBINS has made 0 purchases and 7 sales selling 3,372,000 shares for an estimated $317,471,136.
    • PREM S SHAH (EVP and Group President) purchased 23,855 shares for an estimated $2,001,315

    To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

    EARLY ACCESS
    Receive CVS Data Alerts
    Real-time alerts on filings, insider trades, and market signals — before everyone else.
    Get Alerts →

    $CVS Hedge Fund Activity

    We have seen 967 institutional investors add shares of $CVS stock to their portfolio, and 991 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    • JPMORGAN CHASE & CO added 22,112,970 shares (+inf%) to their portfolio in Q2 2026, for an estimated $2,287,586,746
    • BANK OF AMERICA CORP /DE/ added 13,836,701 shares (+148.0%) to their portfolio in Q2 2026, for an estimated $1,431,406,718
    • SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 13,259,314 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,371,676,033
    • WELLINGTON MANAGEMENT GROUP LLP added 11,233,381 shares (+49.8%) to their portfolio in Q2 2026, for an estimated $1,162,093,264
    • GQG PARTNERS LLC added 7,923,888 shares (+25136.8%) to their portfolio in Q2 2026, for an estimated $819,726,213
    • WCM INVESTMENT MANAGEMENT, LLC added 7,303,377 shares (+inf%) to their portfolio in Q3 2026, for an estimated $625,826,375
    • INVESCO LTD. removed 4,543,515 shares (-18.1%) from their portfolio in Q2 2026, for an estimated $470,026,626

    To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

    $CVS Price Targets

    Multiple analysts have issued price targets for $CVS recently. We have seen 7 analysts offer price targets for $CVS in the last 6 months, with a median target of $110.0.

    Here are some recent targets:

    • Ben Hendrix from RBC Capital set a target price of $113.0 on 07/09/2026
    • Sarah James from Cantor Fitzgerald set a target price of $110.0 on 07/07/2026
    • Allen Lutz from B of A Securities set a target price of $110.0 on 06/23/2026
    • Ann Hynes from Mizuho set a target price of $115.0 on 06/08/2026
    • Erin Wright from Morgan Stanley set a target price of $111.0 on 06/04/2026
    • David Macdonald from Truist Securities set a target price of $108.0 on 06/01/2026
    • Andrew Mok from Barclays set a target price of $106.0 on 05/26/2026

    This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.